Loading…

Targeted Therapies in Oncology Come of Age

[...]the field has expanded exponentially, with more than 40 targeted therapies currently approved by the FDA for the treatment of malignancy.1 Among the best-studied molecular targets, epidermal growth factor receptor (EGFR) ligand binding leads to nuclear transcription via a cascade of linked phos...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical therapeutics 2013-09, Vol.35 (9), p.1256-1257
Main Author:	Klein, Andreas, MD
Format:	Article
Language:	English
Subjects:	Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cancer Cancer therapies Drug Industry Epidermal growth factor FDA approval Humans Internal Medicine Kinases Ligands Medical Education Molecular Targeted Therapy - economics Molecular Targeted Therapy - methods Neoplasms - drug therapy Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics Reproducibility of Results Rodents Signal Transduction - drug effects Signal Transduction - genetics Tumors United States United States Food and Drug Administration
Citations:	Items that this one cites
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by
cites	cdi_FETCH-LOGICAL-c400t-5f7e6db058116ed90c545ad03a360c280cb6f2a0236c385167d92dca1e0fd7e63
container_end_page	1257
container_issue	9
container_start_page	1256
container_title	Clinical therapeutics
container_volume	35
creator	Klein, Andreas, MD
description	[...]the field has expanded exponentially, with more than 40 targeted therapies currently approved by the FDA for the treatment of malignancy.1 Among the best-studied molecular targets, epidermal growth factor receptor (EGFR) ligand binding leads to nuclear transcription via a cascade of linked phosphorylation events amplifying through RAS/MEK/ERK and PI3K/AKT/mTOR, among others.2 EFGR is involved in mediating growth and differentiation in epithelial tissue throughout the body and drives the survival of cancers of epithelial origin, including lung and colorectal, affecting an estimated 228,000 and 143,000 new patients, respectively, in 2013 alone.3 Interestingly, the role of the EGFR pathway appears distinct in these 2 malignancies.
doi_str_mv	10.1016/j.clinthera.2013.08.006
format	article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1435844571</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0149291813008825</els_id><sourcerecordid>1435844571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-5f7e6db058116ed90c545ad03a360c280cb6f2a0236c385167d92dca1e0fd7e63</originalsourceid><addsrcrecordid>eNqNkU2L2zAQhkVp6abb_oXW0Esp2DujL8uXQgj9WFjYw6bQm1CkcarUsVPJKeTfr022W9hTT7o87zujZxh7h1AhoL7aVb6L_fiTkqs4oKjAVAD6GVugqZsSUf54zhaAsil5g-aCvcp5BwCiUfwlu-ASlKyBL9jHtUtbGikU67nsECkXsS9uez90w_ZUrIY9FUNbLLf0mr1oXZfpzcN7yb5_-bxefStvbr9er5Y3pZcAY6namnTYgDKImkIDXknlAggnNHhuwG90yx1wob0wCnUdGh68Q4I2TFFxyT6cew9p-H2kPNp9zJ66zvU0HLNFKZSRUtU4oe-foLvhmPppu5mSCFrWcqLqM-XTkHOi1h5S3Lt0sgh21ml39lGnnXVaMHbSOSXfPvQfN3sKj7m__iZgeQZoEvInUrLZR-o9hZjIjzYM8T-GfHrSMXPRu-4XnSj_-5HN3IK9m686HxUFgDFciXtGtpxA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1434106474</pqid></control><display><type>article</type><title>Targeted Therapies in Oncology Come of Age</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Klein, Andreas, MD</creator><creatorcontrib>Klein, Andreas, MD</creatorcontrib><description>[...]the field has expanded exponentially, with more than 40 targeted therapies currently approved by the FDA for the treatment of malignancy.1 Among the best-studied molecular targets, epidermal growth factor receptor (EGFR) ligand binding leads to nuclear transcription via a cascade of linked phosphorylation events amplifying through RAS/MEK/ERK and PI3K/AKT/mTOR, among others.2 EFGR is involved in mediating growth and differentiation in epithelial tissue throughout the body and drives the survival of cancers of epithelial origin, including lung and colorectal, affecting an estimated 228,000 and 143,000 new patients, respectively, in 2013 alone.3 Interestingly, the role of the EGFR pathway appears distinct in these 2 malignancies.</description><identifier>ISSN: 0149-2918</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2013.08.006</identifier><identifier>PMID: 24054702</identifier><language>eng</language><publisher>United States: EM Inc USA</publisher><subject>Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Cancer ; Cancer therapies ; Drug Industry ; Epidermal growth factor ; FDA approval ; Humans ; Internal Medicine ; Kinases ; Ligands ; Medical Education ; Molecular Targeted Therapy - economics ; Molecular Targeted Therapy - methods ; Neoplasms - drug therapy ; Receptor, Epidermal Growth Factor - antagonists & inhibitors ; Receptor, Epidermal Growth Factor - genetics ; Reproducibility of Results ; Rodents ; Signal Transduction - drug effects ; Signal Transduction - genetics ; Tumors ; United States ; United States Food and Drug Administration</subject><ispartof>Clinical therapeutics, 2013-09, Vol.35 (9), p.1256-1257</ispartof><rights>Elsevier HS Journals, Inc.</rights><rights>2013 Elsevier HS Journals, Inc.</rights><rights>Copyright Elsevier Limited Sep 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c400t-5f7e6db058116ed90c545ad03a360c280cb6f2a0236c385167d92dca1e0fd7e63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24054702$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Klein, Andreas, MD</creatorcontrib><title>Targeted Therapies in Oncology Come of Age</title><title>Clinical therapeutics</title><addtitle>Clin Ther</addtitle><description>[...]the field has expanded exponentially, with more than 40 targeted therapies currently approved by the FDA for the treatment of malignancy.1 Among the best-studied molecular targets, epidermal growth factor receptor (EGFR) ligand binding leads to nuclear transcription via a cascade of linked phosphorylation events amplifying through RAS/MEK/ERK and PI3K/AKT/mTOR, among others.2 EFGR is involved in mediating growth and differentiation in epithelial tissue throughout the body and drives the survival of cancers of epithelial origin, including lung and colorectal, affecting an estimated 228,000 and 143,000 new patients, respectively, in 2013 alone.3 Interestingly, the role of the EGFR pathway appears distinct in these 2 malignancies.</description><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Drug Industry</subject><subject>Epidermal growth factor</subject><subject>FDA approval</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Kinases</subject><subject>Ligands</subject><subject>Medical Education</subject><subject>Molecular Targeted Therapy - economics</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Neoplasms - drug therapy</subject><subject>Receptor, Epidermal Growth Factor - antagonists & inhibitors</subject><subject>Receptor, Epidermal Growth Factor - genetics</subject><subject>Reproducibility of Results</subject><subject>Rodents</subject><subject>Signal Transduction - drug effects</subject><subject>Signal Transduction - genetics</subject><subject>Tumors</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>0149-2918</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqNkU2L2zAQhkVp6abb_oXW0Esp2DujL8uXQgj9WFjYw6bQm1CkcarUsVPJKeTfr022W9hTT7o87zujZxh7h1AhoL7aVb6L_fiTkqs4oKjAVAD6GVugqZsSUf54zhaAsil5g-aCvcp5BwCiUfwlu-ASlKyBL9jHtUtbGikU67nsECkXsS9uez90w_ZUrIY9FUNbLLf0mr1oXZfpzcN7yb5_-bxefStvbr9er5Y3pZcAY6namnTYgDKImkIDXknlAggnNHhuwG90yx1wob0wCnUdGh68Q4I2TFFxyT6cew9p-H2kPNp9zJ66zvU0HLNFKZSRUtU4oe-foLvhmPppu5mSCFrWcqLqM-XTkHOi1h5S3Lt0sgh21ml39lGnnXVaMHbSOSXfPvQfN3sKj7m__iZgeQZoEvInUrLZR-o9hZjIjzYM8T-GfHrSMXPRu-4XnSj_-5HN3IK9m686HxUFgDFciXtGtpxA</recordid><startdate>20130901</startdate><enddate>20130901</enddate><creator>Klein, Andreas, MD</creator><general>EM Inc USA</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20130901</creationdate><title>Targeted Therapies in Oncology Come of Age</title><author>Klein, Andreas, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-5f7e6db058116ed90c545ad03a360c280cb6f2a0236c385167d92dca1e0fd7e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Drug Industry</topic><topic>Epidermal growth factor</topic><topic>FDA approval</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Kinases</topic><topic>Ligands</topic><topic>Medical Education</topic><topic>Molecular Targeted Therapy - economics</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Neoplasms - drug therapy</topic><topic>Receptor, Epidermal Growth Factor - antagonists & inhibitors</topic><topic>Receptor, Epidermal Growth Factor - genetics</topic><topic>Reproducibility of Results</topic><topic>Rodents</topic><topic>Signal Transduction - drug effects</topic><topic>Signal Transduction - genetics</topic><topic>Tumors</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Klein, Andreas, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Klein, Andreas, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted Therapies in Oncology Come of Age</atitle><jtitle>Clinical therapeutics</jtitle><addtitle>Clin Ther</addtitle><date>2013-09-01</date><risdate>2013</risdate><volume>35</volume><issue>9</issue><spage>1256</spage><epage>1257</epage><pages>1256-1257</pages><issn>0149-2918</issn><eissn>1879-114X</eissn><abstract>[...]the field has expanded exponentially, with more than 40 targeted therapies currently approved by the FDA for the treatment of malignancy.1 Among the best-studied molecular targets, epidermal growth factor receptor (EGFR) ligand binding leads to nuclear transcription via a cascade of linked phosphorylation events amplifying through RAS/MEK/ERK and PI3K/AKT/mTOR, among others.2 EFGR is involved in mediating growth and differentiation in epithelial tissue throughout the body and drives the survival of cancers of epithelial origin, including lung and colorectal, affecting an estimated 228,000 and 143,000 new patients, respectively, in 2013 alone.3 Interestingly, the role of the EGFR pathway appears distinct in these 2 malignancies.</abstract><cop>United States</cop><pub>EM Inc USA</pub><pmid>24054702</pmid><doi>10.1016/j.clinthera.2013.08.006</doi><tpages>2</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0149-2918
ispartof	Clinical therapeutics, 2013-09, Vol.35 (9), p.1256-1257
issn	0149-2918 1879-114X
language	eng
recordid	cdi_proquest_miscellaneous_1435844571
source	ScienceDirect Freedom Collection 2022-2024
subjects	Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cancer Cancer therapies Drug Industry Epidermal growth factor FDA approval Humans Internal Medicine Kinases Ligands Medical Education Molecular Targeted Therapy - economics Molecular Targeted Therapy - methods Neoplasms - drug therapy Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics Reproducibility of Results Rodents Signal Transduction - drug effects Signal Transduction - genetics Tumors United States United States Food and Drug Administration
title	Targeted Therapies in Oncology Come of Age
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A31%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20Therapies%20in%20Oncology%20Come%20of%20Age&rft.jtitle=Clinical%20therapeutics&rft.au=Klein,%20Andreas,%20MD&rft.date=2013-09-01&rft.volume=35&rft.issue=9&rft.spage=1256&rft.epage=1257&rft.pages=1256-1257&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2013.08.006&rft_dat=%3Cproquest_cross%3E1435844571%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c400t-5f7e6db058116ed90c545ad03a360c280cb6f2a0236c385167d92dca1e0fd7e63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1434106474&rft_id=info:pmid/24054702&rfr_iscdi=true